Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. - Wikidata - wikimedia - TriplyDB

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

http://www.wikidata.org/entity/Q41503593

about

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers Approaches to modernize the combination drug development paradigm Maximising the potential of AKT inhibitors as anti-cancer treatments Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of β-catenin and of signaling interactions.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Selumetinib in the treatment of non-small-cell lung cancer.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.AKT in cancer: new molecular insights and advances in drug development.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.Structure, signaling and the drug discovery of the Ras oncogene protein.Small molecule drugs with immunomodulatory effects in cancer.Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.MEK inhibitors for the treatment of NRAS mutant melanoma

P2860

Q26781362-37FBD30A-FD60-44D1-B362-4A393F74D195 Q28072074-EC1179B3-3041-450B-939D-093DDAE305EB Q28072254-3C0A65C8-8766-462B-B831-13441DD85F87 Q28080599-2210EFC0-85BC-4363-8594-35EB663EA6E6 Q36117718-DBD10874-1877-4DD2-802E-B6269B5BB357 Q36771749-C36DDBD2-0E67-4EDF-ABF4-069E8B7349D2 Q37684405-195CB928-3DDC-4808-AD49-CD895C0B117D Q37687424-FAB90559-EF49-45E7-B61E-E789C1A2B5DC Q38383457-44E58A76-2404-43F8-A561-BB8786B86F00 Q38733117-230C71B6-8F62-49A6-9FB8-8A5A3E66EF26 Q38761092-244C1D13-69D4-4B09-A49D-1767B5860AA5 Q38786707-55A946ED-8B27-4A4A-9CAF-4673E0EAC90E Q38794338-134A91F3-EB50-4C18-A2D1-330509CEC72B Q38836927-D6AA4FFC-E20D-4C4E-9157-4926AFD0C626 Q38841033-105C40E1-C030-4CA5-A5DA-422A64DA2CC7 Q38846044-149FE62B-1C44-4E09-9496-628884E34172 Q38941928-4FCACEA9-082C-47B0-8E6D-CA7169964444 Q39270291-85723C55-ACC9-40C4-AC74-B2F2B0A1786A Q42353910-16BEDAE4-6FFE-404B-96EC-FD27A7371808 Q45814047-03138E58-31B7-4E6D-A5F2-CB4DBB4B34FC Q47122504-AF8A5CE0-D047-44F2-8BB2-92DB82F5DF98 Q51736090-5D0A354E-EBB3-4FAD-A523-388803ACA2CB Q55332287-F47A8F62-FE38-4557-A39C-E929CC0CEF5C Q56889985-4605165E-6486-4E55-906B-D15F43C9B592

P2860

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

http://www.wikidata.org/entity/Q41503593

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biomarker-driven phase 2 study ...... tients with colorectal cancer.

@en

type

label

Biomarker-driven phase 2 study ...... tients with colorectal cancer.

@en

prefLabel

Biomarker-driven phase 2 study ...... tients with colorectal cancer.

@en

P1433

Q41503593-B797EC4E-A165-4C95-957A-948D09F60E5C

P1476

Q41503593-EAAF995A-E3CC-4A82-95AD-7799F220AFE1

P2093

Q41503593-0B47292F-7508-48CD-A09B-9147C7E77B9D

Q41503593-50EEF395-3E1A-4E89-9D7E-5AA2F203EF04

Q41503593-5C2904ED-1FFB-4577-AE00-724DF975CE45

Q41503593-66189341-E6BB-4DAC-927C-85B6BD0D964C

Q41503593-AAD3CA1C-2986-44CE-80B5-FFA2D69D2D24

Q41503593-B644498B-176B-4724-98BE-B05EC6FD3B64

Q41503593-BE889990-43A2-4F40-A79D-0DD4B5208658

Q41503593-C12A200D-798C-4C78-BFCF-CD8E76789EE2

Q41503593-DB836DA1-4793-4343-AAFB-D3FD59C6757E

Q41503593-E8556BD8-B22C-4BBA-B10C-6E039DAE6721

P2860

Q41503593-1CE873C2-9FD2-4285-8C56-B5DE88FCB6EA

Q41503593-20974EC0-1F95-4D7D-8FC7-4C83931903F3

Q41503593-254C79D4-6D0E-4E20-A88D-7946733C2ECA

Q41503593-2D634C49-CEA4-4E0F-A9E6-CA8DD405AE29

Q41503593-2D6E0365-27DE-4BFF-8377-03ABCCD31D3C

Q41503593-53144E76-F80D-4091-922B-C19F1F8A37EF

Q41503593-750CC29C-33DE-4CEC-9FB6-077F761331E7

Q41503593-953C999F-8F06-44ED-B9E0-8E35B3D8B1FA

Q41503593-B1E0D877-D35D-4830-A911-B0BAE894896E

Q41503593-E246FAE4-082A-46E3-8F5C-C4953DA482B9

P2888

Q41503593-4596D541-F8C0-4917-A2E1-844467E51F5B

P304

Q41503593-FA496E17-E3ED-4C84-8CDC-B647761614A3

P31

Q41503593-8074ABE9-F4AE-4A01-AFE8-A6F5EDC828F4

P356

Q41503593-A3EE7299-D807-4999-8EFE-F0201343E780

P433

Q41503593-D5E06FE8-0E64-4C03-B852-396167F1339D

P478

Q41503593-B94B80FC-F99D-4AFC-9EE6-3AC6BBD81D1F

P50

Q41503593-5CB693E5-D097-41E6-9CA4-E72498E5EA0B

P577

Q41503593-8ADE1C8A-73C4-471A-86BF-0A9570BEB657

P6179

Q41503593-EB06FDFC-8934-4425-90AC-C1EC8E3EDC76

P698

Q41503593-3D02E9E2-BB4A-4209-A631-9349C207047F

P921

Q41503593-16ECF9D5-07E0-46F4-8F3A-FF2E4B2C8C90

Q41503593-34534926-910B-4A75-B92F-E91AEA3BC119

Q41503593-EA5C617B-50A1-4AE7-B882-B4B672FD102C

P356

S10637-015-0212-Z

P1433

Investigational New Drugs

P1476

Biomarker-driven phase 2 study ...... tients with colorectal cancer.

@en

P2093

Giovanna Speranza

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Khanh Do

http://www.w3.org/2001/XMLSchema#string

L Austin Doyle

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Michael H Lam

http://www.w3.org/2001/XMLSchema#string

Michelle Eugeni

http://www.w3.org/2001/XMLSchema#string

Rachel Bishop

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials

The statistics of phase 0 trials.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

P2888

s10637-015-0212-z

P304

720-728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-015-0212-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014328773

http://www.w3.org/2001/XMLSchema#string

P698

25637165

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer